COMPARISON OF POST-OPERATIVE VALUES WITH PRE OPERATIVE VALUES OF CA 15-3 AND ITS PROGNOSTIC VALUE

CHAHAT SEHGAL; SEEMA; MANINDER KAUR; ASHWANI KUMAR

doi:10.22159/ajpcr.2021.v14i11.43078

Authors

CHAHAT SEHGAL Department of Biochemistry, Government Medical College and Rajindra Hospital, Patiala, Punjab, India.
SEEMA Department of Biochemistry, Government Medical College and Rajindra Hospital, Patiala, Punjab, India.
MANINDER KAUR Department of Biochemistry, Government Medical College and Rajindra Hospital, Patiala, Punjab, India.
ASHWANI KUMAR Department of Surgery, Government Medical College and Rajindra Hospital, Patiala, Punjab, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i11.43078

Keywords:

Carcinoma breast, CA 15-3, Effective treatment, Tumor load

Abstract

Objective: This study was designed and conducted to establish the relationship of biomarker CA 15-3 levels with tumor load in cases of carcinoma breast.

Methods: Fifty female patients with confirmed diagnosis of breast malignancy were included in the study. CA 15-3 levels were measured before surgery and after surgery.

Results: It was found that levels of the biomarker were increased in all the cases; the rise was higher in advance cases of carcinoma. Levels decreased after the surgery and this decrease was statistically significant.

Conclusions: It was concluded that levels of CA 15-3 increase in cases of carcinoma breast; higher levels indicate advanced stage and that decrease in levels indicate effective treatment.

Downloads

Download data is not yet available.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal AA, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI: https://doi.org/10.3322/caac.21660

Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics 2020: Report from national cancer registry programme, India. JCO Global Oncol 2020;6:1063-75. DOI: https://doi.org/10.1200/GO.20.00122

Hortobagyi GN, Edge SB, Giuliano A. New and important changes in the TNM staging system for breast cancer. Am Soc Clin Oncol Educ Book 2018;38:457-67. DOI: https://doi.org/10.1200/EDBK_201313

Kilpatrick ES, Lind MJ. Appropriate requesting of serum tumour markers. BMJ 2009;339:b3111. DOI: https://doi.org/10.1136/bmj.b3111

Amayo AA, Kuria JG. Clinical application of tumour markers: A review. East Afr Med J 2009;86 Suppl 12:S76-83. DOI: https://doi.org/10.4314/eamj.v86i12.62909

Duffy JM. Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem 2006;52:345-51. DOI: https://doi.org/10.1373/clinchem.2005.059832

Maric P, Ozretic P, Levanat S, Oreskovic S, Antunac K, Beketic- Oreskovic L. Tumor markers in breast cancereevaluation of their clinical usefulness. Coll Antropol 2011;35:241-7.

Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci 2017;3:5-11. DOI: https://doi.org/10.1016/j.jons.2017.01.001

Hashim ZM. The significance of CA 15-3 in breast cancer patients and its relationship to HER-2 receptor status. Int J Immunopathol Pharmacol 2014;27:45-51. DOI: https://doi.org/10.1177/039463201402700107

Fejzic H, Mujagic S, Azabagic S, Burina M. Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad 2015;44:39-46. DOI: https://doi.org/10.5644/ama2006-124.125

Khan MA, Trivedi HP, Atara AN. Analysis of tumour marker CA 15-3 in breast cancer following surgery. Int Surg J 2016;3:1491-4. DOI: https://doi.org/10.18203/2349-2902.isj20162735

Gupta SK, Kumar V, Anees A, Goel A. The study of prognostic significance of CA 15-3 in breast cancer. Int Surg J 2018;5:580-3. DOI: https://doi.org/10.18203/2349-2902.isj20180356

Khushk M, Khan A, Rehman A, Sheraz S, Tunio YM, Rehman K, et al. The role of tumor markers: Carcinoembryonic antigen and cancer antigen 15-3 in patients with breast cancer. Cureus 2021;13:e16298. DOI: https://doi.org/10.7759/cureus.16298

Popat VC, Mehta SG, Dave N. Evaluation of diagnostic and prognostic role of serum tumour marker CA 15-3 in breast malignancy a retrospective study with the use of 3rd generation ELISA. Indian J Appl Res 2021;11:21-2.